LIU SHEN & ASSOCIATES

ZHANG,Xiaofei

Partner|Patent Attorney

技術分野:

Medical Devices , Bio & Pharmaceutical , Life Science , Chemical Engineering

TEL: 86-10-6268 1616-5025  Phone:13520425353

FAX: 86-10-6268 1818

EMAIL: xfzhang@liu-shen.com

履歴:

Mr. Zhang began his legal career in2003 inSIPO and joined Liu, Shen & Associates in October 2013.

 

Mr. Zhang specializes in patent (including invention, utility model and design) prosecution, invalidation, litigation and counseling, including infringement, validity and FTO analysis in the technical fields of Biotechnology; Pharmaceuticals; Life Sciences; Chemistry; and medical devices.

 

Mr. Zhang worked in the Pharmaceutical and Biotechnology Appeal Division of the Patent Reexamination Board (PRB) from 2007 to May 2013. He served as the chairman of a panel over 5 years, handled a number of important invalidation and reexamination cases including one case chosen to be the Top 10 IP cases of China courts in 2016, and two cases chosen to be the Top 10 cases of PRB in 2010 and 2012. He represented the PRB in patent administrative litigation before Beijing courts, and provided legal and technical expert counseling relating to patent infringement. After joining Liu, Shen & Associates, he takes charge of the cases finally rejected or entering into the reexamination procedure, and several invalidation and litigation cases.

 

Mr. Zhang received his bachelor degree and master degree in Cell Biology fromNanjingNormalUniversityin 2000 and 2003. He finished the postgraduate diploma programmes from China University of Political Science and Law.

 

He received training from John Marshall Law School in 2009, and AIA practice training from Scully, Scott, Murphy & Presser, P.C. in 2016.

活動歴:

Representative cases that Mr. Zhang has led or participated include

-     Novozymes vs. Shandong Longda Bio-products Co., Ltd. for patent invalidation dispute. One of the Top 10 IP cases of China courts in 2016 and one of the Top 10 cases of PRB in 2012. Presiding member of the panel representing the PRB, making the invalidation decision, which maintained the validity of technical solutions defined by structure, sequence homology and source, and winning the suit in the Supreme Court. (2016) Zuigaofa Xing Zai No. 86.

-     Rohm & Haas v. Cabot Microelectronics, invalidation, involving a Chemical Mechanical Polishing composition. On behalf of patentee maintaining the validity of the patent right.

-     Total Petrochemicals v. Versalis, invalidation, involving a foamed material. On behalf of petitioner invaliding the patent right in whole.

-     Arkema v. Chemours Company for patent invalidation dispute (ZL200980116200.0). On behalf of petitioner invaliding the patent right in whole.

-     Tianhepeng vs. Unilever for patent invalidation dispute (ZL200580031702.5). On behalf of petitioner invaliding the patent right in whole.

-     Tianjin Super Biotechnology Developing Co., Ltd vs. Academia Sinica for patent invalidation dispute (ZL200480040177.9). On behalf of patentee maintaining the validity of the patent right.

-     Xi ZHANG vs. ALIBABA Group Holding Ltd for patent invalidation dispute (ZL201620847681.X). On behalf of petitioner invaliding the patent right in whole.

-     Contec vs. ChoiceMMed for patent invalidation dispute. On behalf of petitioner invaliding the patent right in whole.

-     Jianqiao Medicine Dev Co., Ltd vs. Beijing Holleycotec Medicine Co., Ltd. for patent invalidation dispute. One of the Top 10 cases of PRB in 2010. Presiding member of the panel, representing the PRB in patent administrative litigation before Beijing courts, and winning the suit. (2010) Gao Xing Zhong Zi No. 14.

-     Guangzhou Welman Pharma Co., Ltd vs. PRB for patent invalidation dispute. Presiding examiner of the panel making the decision and winning the suit in the Supreme Court. (2012) Zhi Xing Zi No. 5.

-     Guangzhou Welman Pharma Co., Ltd vs. PRB for patent invalidation dispute. Presiding examiner of the panel making the decision and winning the suit. (2011) Gao Xing Zhong Zi No. 299.

-     Ipsen pharma Biotech vs. PRB for patent invalidation dispute. Presiding examiner of the panel making the decision and winning the suit. (2010) Gao Xing Zhong Zi No. 301.

-     Merck vs. Hangzhou Minsheng Pharma for patent invalidation dispute. Presiding examiner of the panel making the decision and winning the suit. (2008) Gao Xing Zhong Zi No. 524.

-     Due Diligence regarding the patent applications of one Biotech company in Wuhan.

-     Due Diligence regarding the product and patent (including patent applications) of one Medical Device company in Shanghai.

-     Due Diligence regarding the product and patent (including patent applications) of one Biotech Pharma company in Shanghai.

-     Due Diligence regarding the ownership of patent (including patent applications) of one Biotech Pharma company in Hangzhou.

-     Due Diligence regarding the product and patent (including patent applications) of one Medical Material company in Qinghuangdao.

-     FTO analysis of Stora Enso.

-     FTO analysis of Total Group.

-     Arkema France v. Chemours, invalidation, involving a refrigerant.

-     Celanese v. Daicel, invalidation, involving acetic acid preparation method.

-     Arkema France v. Honeywell, invalidation, involving a refrigerant.

-     EA pharmaceutical co., LTD v. PRB, administrative litigation, involving a composition.

 

Publications that Mr. Zhang has authored include

-     “China’s Antibody Patent Examination Standards and Reasonable Applicable Proposals in Conjunction with Industry Status”, Chapter 21, p319-341, Biotechnology inHong Kong(Volume II), December 2014.

-     杭州民生药业集团有限公司请求宣告默沙东公司(美国)发明专利无效纠纷案关于创造性判断中技术启示问题的典型案例》,专利名案解读(二)-20起典型专利纠纷案例评析,知识产权出版社,20114.

-    《医药生物领域复审和无效典型案例评析》,编委,知识产权出版社,201411.

-    《权利要求得不到说明书支持味之素相关赖氨酸专利被宣告无效》,《中国医药报》专利商战风云录栏目,20115.

使用言語:

Chinese,English

所属団体:

All-China Patent Agents Association (ACPAA)